Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report

Ahmed Ameen Ismail,Sherin Hassan Sadek,Ragai Magdy Hatata
DOI: https://doi.org/10.1186/s12886-022-02657-8
IF: 2.086
2022-11-16
BMC Ophthalmology
Abstract:Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e.g. systemic lupus erythematosus, rheumatoid arthritis and psoriasis. While it is considered a safe medication, it is well-established that it can cause retinal toxicity i.e. HCQ maculopathy. Guidelines for HCQ retinal toxicity screening include factors like body weight, daily dose, duration, systemic diseases and retinal diseases. In this case study, we report a specific association between CRAO as a retinal disease and early onset HCQ maculopathy in a SLE patient.
ophthalmology
What problem does this paper attempt to address?